This supplement focuses on recent significant advances in the treatment of patients with eye disease. This series of articles by faculty of the University of Illinois at Chicago cover the use of topical, systemic, and biologic agents for allergies, diabetic retinopathy, macular degeneration, glaucoma, and more.
Pharmacotherapy for Ocular Allergy
Managing Diabetic Retinopathy and Age-Related Macular Degeneration
Treating Inflammatory Eye Disease
Pharmacological Approaches to Glaucoma Treatment
Refractive Surgery Update
Roundtable Discussion: Practical Treatment of Eye Disease
The proceedings of the 14th Annual Managed Healthcare Symposium provided a riveting series of presentations and panel discussions about the health policy implications of the aging baby boom cohort. Health plan medical and pharmacy directors, decision makers for integrated health systems and pharmacy benefit managers, and other managed care executives in attendance heard thought-provoking presentations about demographic shifts, drug-related morbidity and mortality, forms of health care rationing, and direct-to-consumer pharmaceutical advertising.
Demographic Shifts: The Age Wave
The Health Care Picture
Healthcare’s Uncertain Future
Impact of Aging on Payer, Provider, and Patient
DTC: A Powerful Tool for Information and Education
Special motivational presentations by Jerri Nielsen, MD, and Mitch Albom
The popularity of several new prescription products in has fostered debate on numerous clinical, economic, and health policy issues. At the Managed Care Summit in 2002, health plan medical and pharmacy directors discussed these issues and listened to presentations about the implications of the rise of previously unheralded therapeutic classes.
The Shaping of Health Care Policy
The Value of Atypical Antipsychotics in the Treatment of Schizophrenia
Impact of Proton Pump Inhibitor Utilization Patterns on Gastroesophageal Reflux Disease-Related Costs
Management of Chronic Pain: A Clinical Overview
Treating Depression: A Focus on Medication Choices from a Clinical and Managed Care Perspective
What defines effective treatment for patients with depression and what are the cost implications of effective and ineffective treatment? This supplement explores the elements that drive clinical and cost outcomes of antidepressive therapy. The presentations herein, derived from the Economic Working Group Advisory Board, cover such subjects as goals of treatment, what constitutes successful outcomes, the comorbid nature of depression, theoretical foundations of an economic model, and the nuances of accurately measuring which costs really matter.
Goals and Challenges of Optimally Treating Depression in a Managed Care Environment
Establishing the Real Cost of Depression
The Economic Model in Theory
The Importance of Adequate Length of Antidepressant Therapy
The SSRI Therapeutic Effective Dose Model
Roundtable Discussion: Assessing the Utility of and Implementing the SSRI Model Within MCOs
This supplement derives from the 2002 Medical Director Colloquy, a forum for interaction between decision makers in managed care and professionals from academic health centers, quality assurance organizations, and the business world. Lipid management involves numerous critical issues, including efficacy and treatment choices. In addition, successful lipid management brings an economic challenge, because it involves a long-term approach to improving care — with results that may not be immediately apparent. This publication, the first of two based on presentations at the 2002 colloquy, places these issues in perspective for medical and pharmacy directors. Additional presentations and continuing education opportunities are available through "Multidisciplinary Management of Dyslipidemia," the second Managed Care supplement from this meeting.
This supplement derives from the 2002 Medical Director Colloquy, a forum for interaction between decision makers in managed care and professionals from academic health centers, quality assurance organizations, and the business world. The second of two publications to address lipid treatment, this supplement provides an important update on managing patients with elevated cholesterol levels by examining advancements in care that minimize risk while maximizing outcomes. The insights provided by Steven E. Nissen, MD, in "Emerging Technologies in Coronary Artery Disease Assessment" is a profound elaboration of the emerging realization that medical science has misunderstood the pathophysiology of coronary artery disease for a half century. Further presentations and continuing education opportunities are available through "Transforming Dyslipidemia Management," the first Managed Care supplement from this meeting.
Optimizing Behavior Change and Minimizing Risk
Emerging Technologies in Coronary Artery Disease Assessment: Insights Provided by Intravascular Ultrasound
Identifying Populations at Risk: Functional Impairment and Emotional Distress
Improving Physician Adherence to Cholesterol Management Guidelines
Will Health Promotion Save Money for Managed Care Organizations? A Decision Framework
As the American population ages, the prevalence of glaucoma rises, thus consuming greater medical and financial resources. For the first time, MCOs are attempting to understand ophthalmologic diseases, their interest driven by the market appearance of several new pharmaceutical products to treat glaucoma. The efficacy of these products has created demand and, in turn, a need for appropriate criteria for their utilization. This digest of existing literature and best practices gives physicians and pharmacists on pharmacy and therapeutics committees up-to-date information about the most efficacious and cost-effective medical treatments available in a centralized format virtually unavailable elsewhere.
Introduction: Glaucoma Arrives on Managed Care’s Doorstep
Prevalence, Utilization, and Economic Implications
Clinical Guidelines for the Treatment of Glaucoma
Glaucoma Medications: A Drug Therapy Review
Considerations in the Pharmacoeconomics of Glaucoma
Current Formulary Status of Glaucoma Agents
Constructing Disease Management Programs for Glaucoma